Is SISI or VINC more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Shineco's return on equity of -79.89% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Shineco -380.55% -79.89% -33.01% Vincerx Pharma N/A -248.33% -132.73%

Do analysts recommend SISI or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shineco 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, SISI or CDT?

Shineco has higher revenue and earnings than CDT Equity. Shineco is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shineco $9.60M 0.00 -$22.45M -$204.00 N/A CDT Equity N/A N/A -$39.22M -$83.86 thousand N/A

Is SISI or CDT more profitable?

CDT Equity has a net margin of 0.00% compared to Shineco's net margin of -380.55%. CDT Equity's return on equity of -72.25% beat Shineco's return on equity. Company Net Margins Return on Equity Return on Assets Shineco -380.55% -79.89% -33.01% CDT Equity N/A -72.25% -55.44%

Which has better valuation & earnings, TRVN or SISI?

Shineco has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevena $443K 0.14 -$40.29M -$47.04 N/A Shineco $9.60M 0.00 -$22.45M -$204.00 N/A

Is TRVN or SISI more profitable?

Trevena has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Trevena's return on equity of 0.00% beat Shineco's return on equity. Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Shineco -380.55% -79.89% -33.01%

Shineco (SISI) Competitors

$0.10 0.00 (0.00%)

As of 10/13/2026

Compare

SISI vs. PTPI, VINC, CDT, CARM, and TRVN

Should you buy Shineco stock or one of its competitors? Shineco's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), CDT Equity (CDT), Carisma Therapeutics (CARM), and Trevena (TRVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Shineco compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Shineco (NASDAQ:SISI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Petros Pharmaceuticals has higher earnings, but lower revenue than Shineco. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$0.36	N/A
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A

Petros Pharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market. Comparatively, Shineco has a beta of -1.76, indicating that its share price is 276% less volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Petros Pharmaceuticals has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Petros Pharmaceuticals' return on equity of -78.22% beat Shineco's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Shineco	-380.55%	-79.89%	-33.01%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Shineco'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Shineco	Neutral

Summary

Petros Pharmaceuticals beats Shineco on 9 of the 11 factors compared between the two stocks.

How does Shineco compare to Vincerx Pharma?

Shineco (NASDAQ:SISI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Shineco's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Shineco	Neutral
Vincerx Pharma	Neutral

Vincerx Pharma has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Shineco's return on equity of -79.89% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Vincerx Pharma	N/A	-248.33%	-132.73%

Shineco has a beta of -1.76, indicating that its share price is 276% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

4.1% of Shineco shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Shineco has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

Shineco and Vincerx Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Shineco compare to CDT Equity?

Shineco (NASDAQ:SISI) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Shineco has a beta of -1.76, suggesting that its share price is 276% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

In the previous week, CDT Equity had 6 more articles in the media than Shineco. MarketBeat recorded 6 mentions for CDT Equity and 0 mentions for Shineco. CDT Equity's average media sentiment score of 0.99 beat Shineco's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Shineco	Neutral
CDT Equity	Positive

CDT Equity has a net margin of 0.00% compared to Shineco's net margin of -380.55%. CDT Equity's return on equity of -72.25% beat Shineco's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
CDT Equity	N/A	-72.25%	-55.44%

Shineco has higher revenue and earnings than CDT Equity. Shineco is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A
CDT Equity	N/A	N/A	-$39.22M	-$83.86 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shineco	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.1% of Shineco shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 0.0% of Shineco shares are owned by insiders. Comparatively, 7.3% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CDT Equity beats Shineco on 7 of the 12 factors compared between the two stocks.

How does Shineco compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Shineco (NASDAQ:SISI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Carisma Therapeutics has a net margin of -254.28% compared to Shineco's net margin of -380.55%. Carisma Therapeutics' return on equity of 0.00% beat Shineco's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Shineco	-380.55%	-79.89%	-33.01%

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Carisma Therapeutics has a beta of -9.6, indicating that its share price is 1,060% less volatile than the broader market. Comparatively, Shineco has a beta of -1.76, indicating that its share price is 276% less volatile than the broader market.

Shineco has lower revenue, but higher earnings than Carisma Therapeutics. Shineco is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Shineco'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Shineco	Neutral

Summary

Carisma Therapeutics beats Shineco on 7 of the 11 factors compared between the two stocks.

How does Shineco compare to Trevena?

Trevena (NASDAQ:TRVN) and Shineco (NASDAQ:SISI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Shineco has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Shineco'saverage media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Shineco	Neutral

Trevena has a beta of -1.99, suggesting that its share price is 299% less volatile than the broader market. Comparatively, Shineco has a beta of -1.76, suggesting that its share price is 276% less volatile than the broader market.

Trevena has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Trevena's return on equity of 0.00% beat Shineco's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Shineco	-380.55%	-79.89%	-33.01%

13.6% of Trevena shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Trevena beats Shineco on 6 of the 11 factors compared between the two stocks.

Get Shineco News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SISI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SISI vs. The Competition

Export

Metric	Shineco	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44K	$12.13B	$7.18B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	0.00	631.84	198.77	18.91
Price / Sales	0.00	747.00	565.69	79.10
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	0.00	9.15	10.51	5.92
Net Income	-$22.45M	$2.82B	$3.50B	$380.90M
7 Day Performance	N/A	-4.55%	-4.32%	-4.38%
1 Month Performance	N/A	-8.50%	-8.64%	-7.25%
1 Year Performance	-88.71%	-6.15%	2.05%	-4.95%

Shineco Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SISI Shineco	N/A	$0.11 flat	N/A	-88.3%	$44K	$9.60M	N/A	119
PTPI Petros Pharmaceuticals	N/A	$0.00 flat	N/A	-85.8%	$103K	$5.11M	N/A	20	Gap Up
VINC Vincerx Pharma	N/A	$0.02 flat	N/A	N/A	$79K	N/A	N/A	60
CDT CDT Equity	1.0233 of 5 stars	$0.80 -4.3%	N/A	-100.0%	$30K	N/A	N/A	4	News Coverage
CARM Carisma Therapeutics	N/A	$0.00 flat	N/A	-98.9%	$21K	$10.77M	0.00	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SISI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shineco (SISI) Competitors

SISI vs. PTPI, VINC, CDT, CARM, and TRVN

How does Shineco compare to Petros Pharmaceuticals?

Summary

How does Shineco compare to Vincerx Pharma?

Summary

How does Shineco compare to CDT Equity?

Summary

How does Shineco compare to Carisma Therapeutics?

Summary

How does Shineco compare to Trevena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SISI vs. The Competition

Shineco Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shineco (SISI) Competitors

SISI vs. PTPI, VINC, CDT, CARM, and TRVN

How does Shineco compare to Petros Pharmaceuticals?

Which has preferable earnings & valuation, PTPI or SISI?

Which has more volatility & risk, PTPI or SISI?

Do institutionals & insiders hold more shares of PTPI or SISI?

Is PTPI or SISI more profitable?

Does the media prefer PTPI or SISI?

Summary

How does Shineco compare to Vincerx Pharma?

Does the media favor SISI or VINC?

Is SISI or VINC more profitable?

Which has more risk and volatility, SISI or VINC?

Do insiders & institutionals believe in SISI or VINC?

Which has higher earnings and valuation, SISI or VINC?

Summary

How does Shineco compare to CDT Equity?

Which has more volatility and risk, SISI or CDT?

Does the media favor SISI or CDT?

Is SISI or CDT more profitable?

Which has stronger earnings and valuation, SISI or CDT?

Do analysts recommend SISI or CDT?

Do institutionals and insiders hold more shares of SISI or CDT?

Summary

How does Shineco compare to Carisma Therapeutics?

Is CARM or SISI more profitable?

Do insiders and institutionals have more ownership in CARM or SISI?

Which has more volatility and risk, CARM or SISI?

Which has better earnings and valuation, CARM or SISI?

Does the media refer more to CARM or SISI?

Summary

How does Shineco compare to Trevena?

Which has better valuation & earnings, TRVN or SISI?

Does the media prefer TRVN or SISI?

Which has more volatility & risk, TRVN or SISI?

Is TRVN or SISI more profitable?

Do insiders and institutionals believe in TRVN or SISI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SISI vs. The Competition

Shineco Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools